LeMaitre Vascular

LeMaitre Vascular is a Boston-based specialty medical-device company focused exclusively on peripheral vascular surgery — bypass grafts, carotid shunts, embolectomy and thrombectomy catheters, allografts (cryopreserved human tissue), and surgical sealants. The CEO George LeMaitre and his family hold approximately 14% of shares and have driven 25 years of organic-plus-acquired growth into more than 30 niche product lines.

The thesis the market underweights: LeMaitre runs a roll-up strategy in a fragmented vascular-surgery niche where no single competitor cares to compete in product lines under 30M USD revenue. The company has completed 20+ acquisitions averaging 3-8M USD each, each acquired at 1.0-1.5x revenue and reaccelerated post-acquisition through LeMaitre direct sales force in 65 markets. The aggregate revenue base of approximately 250M USD compounds at 11-13% with 30-32% adjusted EBITDA margins.

Three structural tailwinds in 2026: peripheral artery disease prevalence is rising with aging demographics across the US, EU, and Japan; the carotid stent versus carotid endarterectomy debate is settling toward endarterectomy in symptomatic patients, driving LeMaitre carotid shunt volume; and the cryopreserved-allograft segment (the Cryolife purchase in 2023) is reaching critical mass with 18-22% organic growth. At 97.31 USD the stock trades at 30x forward earnings with peer median at 24-32x for niche medtech compounders.

The dominant holder is the LeMaitre family with approximately 14% of shares — CEO George LeMaitre and his brother David LeMaitre (former CEO, now chairman) hold the bulk. The family has been a long-term holder and has not net sold since 2018; small Rule 10b5-1 program sales by George are typical end-of-quarter tax disposals.

External institutional holders skew toward small-cap-quality-growth funds. Wasatch Advisors (Salt Lake City) is the largest at 6.8% and has held since 2017. Conestoga Capital Advisors at 4.2% and Champlain Investment Partners at 3.4% are both well-known small-cap-quality specialists with multi-year horizons. Vanguard and BlackRock together hold 16% via index exposure.

Insider activity in 2025-2026 was mixed. CFO J.J. Pellegrino made a 1,500-share open-market purchase at 95 USD in March 2026 — first open-market buy since 2022. CEO George LeMaitre executed normal-course 10b5-1 sales of approximately 4,000 shares per quarter at average 105 USD across 2025. No discretionary insider selling. The 2025 dividend was raised 15% to 0.65 USD annualized.

LeMaitre trades at 30x forward 2026 EPS of 3.25 USD versus peer median at 24-32x for niche medtech compounders (Globus Medical, NuVasive, Penumbra). EV/EBITDA at 22x is in line with peer median 20-24x. Sell-side targets range from 95 USD (Truist, bear case at slowing hospital procedure volume) to 135 USD (Needham, bull case at full Cryolife scale plus 2 acquisitions per year). Fair value at 115-120 USD implies 18-23% upside from current 97.31 USD. The 1.03% dividend yield is a small but growing capital-return component — 15% annual dividend growth since 2018.

1. Q3 2026: Second 2026 bolt-on acquisition announcement — incremental signal on M&A pipeline discipline
2. Q4 2026: Cryolife allograft segment annual revenue print at 18-22 percent organic growth
3. Q2 2027: International segment EBIT margin expansion announcement — UK, Germany, France direct salesforce scale benefits

LeMaitre is a textbook compounder: founder-family ownership at 14%, disciplined roll-up strategy in a fragmented niche, predictable 11-13% organic growth plus accretive bolt-ons, and 30%+ adjusted EBITDA margins. The 30x forward earnings multiple is on the high side but defensible against quality compounder peers. The risk is hospital procedure volume sensitivity which limits short-term ceiling. I size LMAT at 1-2% as a long-duration compounder with 18-24 month target 115-120 USD and 3-5 year compounding return potential. Suitable for buy-and-hold IRA accounts more than active trading positions.